Work Productivity Measures Research Articles

Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem.

Patients with irritable bowel syndrome (IBS) are more likely to be both absent from and impaired at work compared to non-IBS patients. We investigated the impact of IBS on work productivity and activity impairment and the relationship to disease specific and general health measures. In total, 525 patients with IBS completed questionnaires assessing work productivity and activity impairment, IBS symptom severity, IBS-related quality of life and GI-specific anxiety. In addition, 155 of the patients completed questionnaires assessing severity of somatic symptoms, depression, anxiety and fatigue. Uni- and bivariate analyses were performed, as well as linear regression to determine factors independently associated with the work productivity and activity impairment measures. Of employed patients, 24.3% reported absenteeism and 86.8% reported presenteeism because of their IBS. With increasing severity of IBS symptoms and GI-specific anxiety, higher degrees of work impairment were seen. Work productivity impairment in IBS was also associated with low quality of life. GI-specific anxiety was independently associated with absenteeism (R2 = 0.23; p < 0.05), IBS-symptom severity and general fatigue with presenteeism (R2 = 0.40; p < 0.05), IBS-symptom severity, general fatigue and GI-specific anxiety with overall work loss (R2 = 0.50; p < 0.05), and IBS symptom severity and somatic symptoms with activity impairment (R2 = 0.38; p < 0.05). Work impairment is a substantial problem in patients with IBS. A combination of IBS and somatic symptom severity, fatigue and psychological factors influence patients' ability to be present, active and productive at work. Based on this, a multidimensional treatment approach for patients with IBS seems logical.

0621 Measures of Function, Work Productivity, and Quality of Life From a Phase 3 Study of Solriamfetol (JZP-110) in Patients with Narcolepsy

0621 Measures of Function, Work Productivity, and Quality of Life From a Phase 3 Study of Solriamfetol (JZP-110) in Patients with Narcolepsy

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

BackgroundThis study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs.MethodsPatients were randomized 4:3:4 to MTX administered once weekly (N = 210), baricitinib monotherapy (4 mg once daily (QD), N = 159), or combination of baricitinib (4 mg QD) and MTX (baricitinib + MTX, N = 215). PROs included the Patient’s Global Assessment of Disease Activity (PtGA), patient's assessment of pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), duration of morning joint stiffness (MJS), worst joint pain, worst tiredness, Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA), Short Form 36 version 2, Acute (SF-36); and EuroQol 5-Dimensions (EQ-5D) Health State Profile. Comparisons were assessed with analysis of covariance (ANCOVA) and logistic regression models.ResultsCompared to MTX, patients in both baricitinib groups reported greater improvement (p ≤ 0.01) in HAQ-DI, PtGA, pain, fatigue, worst join pain, SF-36 physical component score, and EQ-5D at weeks 24 and 52. For the SF-36 mental component score, patients in both baricitinib groups reported statistically significant improvements (p ≤ 0.01) at week 52 compared to MTX-treated patients. Statistically significant improvements (p ≤ 0.05) were observed with the WPAI-RA for the baricitinib groups vs. MTX at week 24 and for the WPAI-RA daily activity and work productivity measures for baricitinib + MTX at week 52.ConclusionsIn this study, baricitinib alone or in combination with MTX, when used as initial therapy, resulted in significant improvement compared to MTX in the majority of the pre-specified PRO measures.Trial RegistrationClinicalTrials.gov, NCT01711359. Registered on 18 October 2012.

Health-Related Quality of Life (HRQoL) and Changes in Work Productivity Measures with Subcutaneous C1-Inhibitor [C1-INH(SC)] for the Prevention of Hereditary Angioedema (HAE) Attacks: Findings from the Compact Study

Health-Related Quality of Life (HRQoL) and Changes in Work Productivity Measures with Subcutaneous C1-Inhibitor [C1-INH(SC)] for the Prevention of Hereditary Angioedema (HAE) Attacks: Findings from the Compact Study

Development of a voice disorder work productivity inventory utilizing cognitive interviewing technique.

Objectives/HypothesisVoice disorders have been shown to impair workplace productivity primarily by reduced efficiency while at work (presenteeism) versus increased days missed (absenteeism). Work productivity measures such as the Work Productivity and Activity Impairment (WPAI) Questionnaire or the World Health Organization Health ‐ Work Performance Questionnaire (HPQ) can be customized to a specific disease but do not fully capture impaired work productivity associated with voice disorders. The purpose of this study was to develop a novel questionnaire to evaluate work productivity in patients with voice disorders.Study DesignDescriptiveMethodsAt a tertiary medical center, patients with gainful employment and with chronic voice disorders were given the WPAI, HPQ, and 20 voice‐related statements (VRS‐20). Cognitive interviews were conducted and recorded with all patients.ResultsTen patients (7 females, 3 males) completed the questionnaires and subsequent cognitive interviews. One patient had spasmodic dysphonia, 6 had benign vocal fold lesions, and 3 had vocal fold motion disorders. The median VHI‐10 was 18 (9‐40). Themes that emerged during interviews include: avoiding oral communication/telephone, use of voice associated with strain/fatigue, frustration and stress at work, and workplace integrity. Conclusions: In cognitive interviews, participants felt the VRS‐20 captured the impact of their voice disorder at work better than the WPAI and HPQ. Participants also felt some statements were more important than others.Level of Evidence5.

My Better Self

Character strengths are hypothesized to contribute to human thriving. However, the effects of their use on individuals’ behaviors and attitudes at work, an important domain of modern life, have rarely been studied. In the present study, we examined associations of employees’ use of character strengths at work with productivity, organizational citizenship behavior (OCB), and job satisfaction. Based on the broaden-and-build theory of positive emotions, we suggested a multiple mediation model demonstrating how these associations are mediated by positive affect and engagement. Participants ( N = 1,095) completed measures of strengths use, work productivity, OCB, job satisfaction, positive affect, and work engagement. As hypothesized, using strengths at work was associated with productivity, OCB, and job satisfaction, and these associations were mediated by higher positive emotions and engagement. The findings highlight the potential benefits of encouraging employees to use their strengths and point to positive affect and work engagement as mediating these effects.

The Influence of Career Stage on Police Officer Work Behavior

Career stage theory suggested that workers progress through career stages, each marked by unique work attitudes. Little evidence exists, however, about the influence career stages have on the work activities of criminal justice agents. Using a sample of 401 police officers from 23 individual police departments, the present study examined the influence of employee career stage on three measures of work productivity, and the constructs of expectancy motivation theory. The results revealed curvilinear declines in productivity with progression through the career stages. The predictive values of opportunity, ability, and instrumentality on work activities varied with career stage and type of work output. Only performance-reward expectancy retained predictive value across all career stages and outputs. The findings emphasize the importance of intrinsic and informal extrinsic rewards for the management of experienced criminal justice agents.

Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity.

ObjectiveMany stroke survivors experience poststroke spasticity and the related inability to perform basic activities, which necessitates patient management and treatment, and exerts a considerable burden on the informal caregiver. The current study aims to estimate burden, productivity loss, and indirect costs for caregivers of stroke survivors with spasticity.MethodsInternet survey data were collected from 153 caregivers of stroke survivors with spasticity including caregiving time and difficulty (Oberst Caregiver Burden Scale), Work Productivity and Activity Impairment measures, and caregiver and patient characteristics. Fractional logit models examined predictors of work-related restriction, and work losses were monetized (2012 median US wages).ResultsMean Oberst Caregiver Burden Scale time and difficulty scores were 46.1 and 32.4, respectively. Employed caregivers (n=71) had overall work restriction (32%), absenteeism (9%), and presenteeism (27%). Caregiver characteristics, lack of nursing home coverage, and stroke survivors’ disability predicted all work restriction outcomes. The mean total lost-productivity cost per employed caregiver was US$835 per month (>$10,000 per year; 72% attributable to presenteeism).ConclusionThese findings demonstrate the substantial burden of caring for stroke survivors with spasticity illustrating the societal and economic impact of stroke that extends beyond the stroke survivor.

The effectiveness of interventions for ageing workers on (early) retirement, work ability and productivity: a systematic review.

To systematically summarise the literature on the effects of interventions for ageing workers that address work-related measures of sustainable employability, i.e. (early) retirement, work ability and work productivity. A systematic review was performed by searching five electronic databases for relevant studies published between January 1992 and February 2014. Randomised controlled trials (RCTs) and quasi-experimental intervention studies were included. The study population included workers aged ≥40 years, and the measured outcomes were positive indicators of labour force participation, i.e. (early) retirement, work ability and work productivity. The methodological quality of each included study was assessed, and best-evidence synthesis was applied to draw conclusions about the evidence for the effectiveness of each outcome. Four studies met the inclusion criteria. The interventions were diverse and ranged from individual (e.g. exercise) programmes to workplace programmes. Limited evidence for a favourable effect on early retirement was found. Insufficient evidence was found for the remaining outcomes, i.e. work ability and productivity, due to a lack of high-quality studies and consistent findings. Insufficient and limited evidence is available for a favourable effect of interventions to promote work-related components of sustainable employability in ageing workers. This is due to a scarcity of RCTs and inconsistent findings between the limited number of studies. Additional intervention studies are needed to support evidence-based decision making to prolong a healthy and productive working life for ageing workers.

Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance.

BackgroundDespite overall progress in treatment of autoimmune diseases, patients with systemic lupus erythematosus (SLE) experience many inflammatory symptoms representing an unmet medical need. This study aimed to create a conceptual model of the humanistic and economic burden of SLE, and review the patient-reported outcomes (PROs) used to measure such concepts in SLE clinical trials.MethodsA conceptual model for SLE was developed from structured review of published articles from 2007 to August 2013 identified from literature databases (MEDLINE, EMBASE, PsycINFO, EconLit) plus other sources (PROLabels, FDA/EMA websites, Clinicaltrials.gov). PROs targeting key symptoms/impacts were identified from the literature. They were reviewed in the context of available guidance and assessed for face and content validity and psychometric properties to determine appropriateness for use in SLE trials.ResultsThe conceptual model identified fatigue, pain, cognition, daily activities, emotional well-being, physical/social functioning and work productivity as key SLE concepts. Of the 68 articles reviewed, 38 reported PRO data. From these and the other sources, 15 PROs were selected for review, including SLE-specific health-related quality of life (HRQoL) measures (n = 5), work productivity (n = 1), and generic measures of fatigue (n = 3), pain (n = 2), depression (n = 2) and HRQoL (n = 2). The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue), Brief Pain Inventory (BPI-SF) and LupusQoL demonstrated the strongest face validity, conceptual coverage and psychometric properties measuring key concepts in the conceptual model. All PROs reviewed, except for three Lupus-specific measures, lacked qualitative SLE patient involvement during development. The Hospital Anxiety and Depression Scale (HADS), Short Form [36 item] Health Survey version 2 (SF-36v2), EuroQoL 5-dimensions (EQ-5D-3L and EQ-5D-5L) and Work Productivity and Activity Impairment Questionnaire: Lupus (WPAI:Lupus) showed suitability for SLE economic models.ConclusionsBased on the identification of key symptoms and impacts of SLE using a scientifically sound conceptual model, we conclude that SLE is a condition associated with high unmet need and considerable burden to patients. This review highlights the availability and need for disease-specific and generic patient-reported measures of relevant domains of disease signs and symptoms, HRQoL and work productivity, providing useful insight for SLE clinical trial design.

FRI0152 Decreased Employment, Work Productivity, and Presenteeism in Patients with Ankylosing Spondylitis is Associated with Increased Disease Activity as Measured by Basdai

BackgroundAnkylosing spondylitis (AS) results in substantial burden to patients. The Bath AS Disease Activity Index (BASDAI) has been used as a primary endpoint in clinical trials involving patients with AS;...

Su2082 Colonic Barrier Function Is Impaired in Post-Campylobacter jejuni Irritable Bowel Syndrome

Background: IBS is one of the most prevalent functional gastrointestinal disorders. Earlier studies have shown that IBS patients are more likely to be impaired at work and during daily activities compared to non-IBS patients. However, factors of importance for this impairment have not yet been fully examined. Aim: To investigate the relationship between work impairment and other factors related to IBS. Methods: We included 533 patients with IBS (median age 34 (17-80) years, 420 females). The patients completed the Work Productivity and Activity Impairment Questionnaire:IBS (WPAI:IBS), as well as questionnaires to assess IBS symptom severity (IBS-SSS), GI-specific anxiety (VSI), somatic symptoms (PHQ-15), depression and anxiety (HAD), and fatigue (MFI). Uniand bivariate analyses were performed, as well as linear regression analyses to determine factors independently associated with the work productivity and activity impairment measures. Results: The IBS patients reported 7±19% (mean±SD) absenteeism (actual work time missed), 33±25% presenteeism (impairment while at work), 36±27% overall work productivity loss and 46±27% activity impairment. Female IBS patients reported greater activity impairment than males (47±27 vs. 41±27 %; p<0.05), but no other gender differences were found. A weak, but statistically significant negative association was noted between age and activity impairment (rho=-0.11; p<0.05), but otherwise age was not associated with the work productivity and activity impairment. No differences between IBS-subtypes were found. With increasing severity of IBS symptoms, somatic symptoms and GI-specific anxiety, higher degrees of absenteeism, presenteeism, overall work productivity loss and activity impairment were seen (p<0.0001 for all). Among the fatigue measures, physical fatigue, general fatigue and reduced activity demonstrated the strongest associations with the work productivity and activity impairment (rho=0.280.47; p<0.01). Weaker, but still statistically significant associations were seen between general anxiety and depression and presenteesim, overall productivity loss and activity impairment (rho=0.19-0.30; p<0.05). Using linear regression analysis, IBS symptom severity, GI-specific anxiety and general fatigue were independently associated with presenteeism (R=0.36; p<0.05) and overall productivity loss (R2=0.42; p<0.05), while activity impairment was independently associated with IBS symptom severity and general fatigue (R2=0.40; p<0.05). Conclusions:Work productivity and activity impairment is a substantial problem in patients with IBS. A combination of IBS and somatic symptom severity, fatigue and psychological factors seem to impact the IBS patients' ability to be active and productive at work. Based on this, a multidimensional treatment approach for IBS patients seems logical.

Voice disorders in the workplace: Productivity in spasmodic dysphonia and the impact of botulinum toxin

The impact of the disordered voice on standard work productivity measures and employment trends is difficult to quantify; this is in large part due to the heterogeneity of the disease processes. Spasmodic dysphonia (SD), a chronic voice disorder, may be a useful model to study this impact. Self-reported work measures (worked missed, work impairment, overall work productivity, and activity impairment) were studied among patients receiving botulinum toxin (BTX) treatments for SD. It was hypothesized that there would be a substantial difference in work-related measures between the best and worst voicing periods. In addition, job types, employment shifts, and vocal requirements during the course of vocal disability from SD were investigated for each individual, and the impact of SD on these patterns was studied. A total of 145 patients with SD, either adductor or abductor, who were established in routine therapeutic BTX injections agreed to participate in a self-administered questionnaire study. Seventy-two participants were currently working and provided highly detailed information on work-related measures. Their answers characterized the effect of SD on their employment status, productivity at work, activity impairment outside of work, employment retention or change, and whether the individual perceived that BTX therapy affected these measures. Patients were asked to complete the Work Productivity and Activity Impairment (WPAI) instrument to determine these measures for their best and worst voicing weeks over the duration since their previous BTX injection. Voice-specific quality of life instruments (Voice Handicap Index-10) and perceptual assessments (Consensus Auditory Perceptual Evaluation of Voice) were elicited to provide correlations of work measures with patient-perceived voice handicap and clinician-perceived voice quality. Cross-sectional analysis using self-administered questionnaire. A total of 108 patients reported ever working during their diagnosis and treatment of SD, and 72 patients were currently working and had undergone BTX therapy for at least 1 year at the time of the analysis. Currently employed patients reported a mean 4.4% decrease in work missed (absenteeism), a 28.1% decrease in work impairment (presenteeism), a 29.4% decrease in work productivity, and a 21.4% decrease in activity impairment (P <.001) in their best, as compared to their worst voicing period over their last BTX injection cycle. Presenteeism accounted for the major component of the percent work productivity impairment calculation. There was neither apparent shift in job categories nor any change in the vocal demands of their employment over the course of their disease. Among patients that have worked during their diagnosis of SD, greater than 98% report that BTX injections helped them at work. Patients with SD reported that their vocal dysfunction caused a significant negative effect on work productivity and increase in activity impairment. There was a significant improvement in their voice-related work parameters from their worst to best voicing periods over their last BTX injection cycle. Patients undergoing long-term BTX treatment report a positive effect of this treatment in their workplace. Spasmodic dysphonia is a meaningful model in which to study the effects of voice disorders on work productivity and employment patterns.

Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study

Psoriasis is known to have a significant negative impact on a patient's health-related quality of life, including social, recreational and work activities. To evaluate the effects of briakinumab on quality of life and work productivity measures in patients with moderate to severe psoriasis. Patients received either briakinumab (n = 981) or placebo (n = 484) during the 12-week induction phase of trial M06-890. At week 12, patients with a Physician's Global Assessment score of 'Clear' or 'Minimal' entered the 40-week maintenance phase and were to receive briakinumab every 4 weeks, briakinumab every 12 weeks, or placebo. At weeks 12 and 52, treatment groups were compared using mean change from baseline in health-related quality of life and Work Productivity and Activity Impairment Questionnaire scores and the percentage of patients with minimum clinically important differences. At week 12, more than half of the briakinumab-treated patients achieved improvements meeting or exceeding minimum clinically important differences for Dermatology Life Quality Index (75.9%), and psoriasis- (64.8%), and psoriatic arthritis-related (54.1%) pain scores; 48.4% achieved improvements for activity impairment. Although improvements in quality of life and work productivity measures were maintained at week 52 for both briakinumab regimens, responder rates were consistently greater in the every-4-week group than in the every-12-week group. Briakinumab treatment resulted in clinically significant improvements in quality of life and work productivity in adults with moderate to severe psoriasis. Maintenance therapy was associated with a more pronounced benefit for the every-4-week briakinumab regimen.

Relationship Between Self-reported Low-back Pain Severity and Other Patient-reported Outcomes

A cross-sectional observational study of physicians and patients with chronic low-back pain (CLBP) in the United States. To evaluate the association of patient-reported CLBP severity with other patient-reported outcomes. Appropriate management of patients with CLBP can be enhanced by understanding how patients perceive the severity of their CLBP. Data were from the 2009 Adelphi Disease Specific Programme. Patients reported the severity of their CLBP condition by answering the question Please rate how your chronic lower back pain condition is today with responses of mild, moderate, and severe. Patient-reported severity was evaluated with respect to scores on standard patient self-report measures of pain, pain interference, health status, functional disability, work productivity, and questions addressing satisfaction with medications for treating CLBP. Of 1860 subjects in the CLBP database, 1363 (73.3%) agreed to complete the survey. This sample was similarly distributed between males (49%) and females (51%), with mean age 54.8 years: 52% were employed at least part-time. CLBP severity was rated as mild, moderate and severe by 28.6%, 53.3%, and 18.2% of patients, respectively. With increasing CLBP severity, significant differences were observed in increased pain (P<0.0001), pain interference with function (P<0.0001), and impairment while working due to CLBP (P<0.01), mainly due to presenteeism. Increased work impairment resulted in higher costs related to lost work productivity; annual lost productivity costs were estimated at $7080, $16,616, and $25,032 per patient for mild, moderate, and severe CLBP, respectively (P<0.0001 for pairwise comparisons). Patient satisfaction with pain-related medication was inversely associated with CLBP severity. The association between patient-reported CLBP severity and other patient-reported outcomes demonstrates that in the clinical setting, patient-reported CLBP severity provides an accurate and suitable indicator of patient-reported health status. This indicator may be useful for guiding management strategies for CLBP patients.

Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS).

111 Background: Limited data exist on patient (pt) experience and work productivity (WP) in MBC. VIRGO is a prospective OCS following &gt;1,200 pts with locally advanced or MBC receiving 1st-line hormonal therapy (HT) or chemotherapy (CT) in a real-world setting. We report baseline characteristics of 277 pts from the VIRGO PRO substudy and correlations between health-related quality of life (HRQoL), symptoms, activities of daily living, and WP. Methods: Symptom severity and interference (M.D. Anderson Symptom Inventory [MDASI]), functional status (Activity Level Scale [ALS] from the Rotterdam Symptom Checklist) and WP (Work Productivity and Activity Impairment Questionnaire) were assessed. Pts rated their HRQoL during the past week on a scale of 0–10. Results: See table. The five most severe symptoms at baseline were fatigue, decreased sexual interest, disturbed sleep, drowsiness, and emotional distress; these were reported with less severity in the HT cohort (24%-37% vs 42%-59%). Overall MDASI severity and interference correlated with WP measures in the CT (R=0.46 to 0.78) and HT cohorts (0.36 to 0.94). Mean of the 5 most severe symptoms also significantly correlated with WP indices (R=0.47 to 0.66). HRQoL correlated (p&lt;0.05) with all WP measures (R=-0.46 to -0.56) in the CT cohort and with % impairment while working (R=-0.65) and % overall work impairment (R=-0.71) in the HT cohort. In univariate regression analysis, MDASI symptom interference score was the best predictor of reduced WP (R2=0.52 while working; R2=0.48 for non-work activities). Conclusions: MBC pts receiving CT and HT report significant work impairment. Results indicate moderate correlations between WP indices, HRQoL and symptom burden. [Table: see text]

Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS).

e11051 Background: Limited data exist on patient (pt) experience and work productivity (WP) in MBC. VIRGO is a prospective OCS following &gt;1200 pts with locally advanced or MBC receiving 1st-line hormonal therapy (HT) or chemotherapy (CT) in a real-world setting. We report baseline characteristics of 277 pts from the VIRGO PRO substudy and correlations between health-related quality of life (HRQoL), symptoms, activities of daily living, and WP. Methods: Symptom severity and interference (MD Anderson Symptom Inventory [MDASI]), functional status (Activity Level Scale [ALS] from the Rotterdam Symptom Checklist) and WP (Work Productivity and Activity Impairment Questionnaire) were assessed. Pts rated their HRQoL during the past week on a scale of 0–10. Results: See table. The five most severe symptoms at baseline were fatigue, decreased sexual interest, disturbed sleep, drowsiness, and emotional distress; these were reported with less severity in the HT cohort (24%-37% vs 42%-59%). Overall MDASI severity and interference correlated with WP measures in the CT (R = 0.46 to 0.78) and HT cohorts (0.36 to 0.94). Mean of the five most severe symptoms also significantly correlated with WP indices (R = 0.47 to 0.66). HRQoL correlated (p &lt; 0.05) with all WP measures (R = -0.46 to -0.56) in the CT cohort and with % impairment while working (R = -0.65) and % overall work impairment (R = -0.71) in the HT cohort. In univariate regression analysis, MDASI symptom interference score was the best predictor of reduced WP (R2 = 0.52 while working; R2 = 0.48 for nonwork activities). Conclusions: MBC pts receiving CT and HT report significant work impairment. Results indicate moderate correlations between WP indices, HRQoL and symptom burden. [Table: see text]

Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS‐RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA‐WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI)

Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS‐RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA‐WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI)

Productivity, Investment in Human Capital and the Challenge of Youth Employment in Sub-Saharan Africa: Comparative Developments and Global Responses in the Perspective of School-to-Work Transition

Productivity, Investment in Human Capital and the Challenge of Youth Employment in Sub-Saharan Africa: Comparative Developments and Global Responses in the Perspective of School-to-Work Transition

Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohnʼs disease version

The Work Productivity and Activity Impairment questionnaire has only been partially validated in Crohn's disease. To test the Work Productivity and Activity Impairment questionnaire for use in Crohn's disease patients. A validated Spanish translation of the test was assessed. 'Discriminant validity' was evaluated by comparing Work Productivity and Activity Impairment scores in Crohn's disease patients with active versus inactive disease, and in patients versus healthy controls. 'Convergent validity' was tested comparing Work Productivity and Activity Impairment questionnaire with quality of life, Crohn's disease activity index and a debriefing questionnaire. 'Reproducibility' of repeated tests was evaluated by comparing two Work Productivity and Activity Impairment measures obtained 2 weeks apart in stable patients. 'Responsiveness' was determined by comparing Work Productivity and Activity Impairment values in the same patients during a flare-up of Crohn's disease and during remission. The Wilcoxon test for paired data and the Mann-Whitney U test for unpaired data were used for comparisons. One hundred and six patients were included in the various steps of the analysis. All Work Productivity and Activity Impairment parameters showed adequate discriminant and convergent validity and responsiveness. The test's reproducibility was also adequate, except for the evaluation of presenteeism (the impairment of productivity while working). The Spanish Work Productivity and Activity Impairment questionnaire is a valid and reliable measurement of work impairment in Crohn's disease. Unexpectedly, the test did not present satisfactory reproducibility for the evaluation of presenteeism. The reliability of this last finding should be evaluated in further studies.